Pellets vs a Metered Spray: Four Months Fixed, or One Day at a Time

A testosterone pellet implant is a minor procedure that delivers hormone for roughly four months. A metered transdermal spray is applied once a day. Both bypass the liver, which is the problem every testosterone product has to solve.[1] The difference that matters clinically is not needles versus no needles — it is reversibility.

What the pellet data actually shows

Pellet dosing has been common practice for longer than it has been well characterised. An open-label study implanted 12 pellets — 900 mg — in 15 men with androgen deficiency and measured hormones by validated liquid chromatography and tandem mass spectrometry at days 1, 5, 8, 15, 29, 57, 85 and 113.[2]

Mean testosterone concentrations fluctuated during the first 2 weeks (range 300–1,000 ng/dL) but remained at or above 300 ng/dL through day 113.[2]

That is the case for pellets, stated fairly: one procedure, and adequate concentrations sustained for about four months. Free testosterone, DHT and estradiol mirrored total testosterone.[2] Most patients were "very satisfied" (40.0%) or "quite satisfied" (26.7%).[2]

Two caveats belong with it, and the authors state both. The study was open-label, uncontrolled, small (15 men) and ethnically non-diverse, which particularly limits the patient-reported outcomes.[2] And the background to the study is itself notable: implantation of 150–450 mg is common clinical practice despite a lack of prospective data.[2]

Adverse events were few. Pellet extrusion and polycythemia each occurred in one patient.[2] Extrusion — the pellet working its way back out through the incision — has no equivalent in any topical product.

The comparison

	Pellets	Metered transdermal spray
Administration	Minor in-office implant procedure	Self-applied, daily
Duration per administration	Concentrations sustained to ~day 113 in the 900 mg study[2]	One day
Curve within the period	Fluctuates over the first two weeks, 300–1,000 ng/dL[2]	Daily application, daily curve
Adjusting the dose mid-course	Not possible without removing the implant	Change at the next dose
Formulation-specific risks	Extrusion; procedure site	Transfer to others before it dries
Evidence base	Limited prospective data; the 900 mg study is small and open-label[2]	Published transdermal spray pharmacokinetics in healthy males[3]

Why reversibility is the real axis

Testosterone therapy is not a fixed prescription. Doses get adjusted after the first labs, symptoms change, hematocrit rises in some men and forces a change, and a proportion of men stop within the first year.

A daily topical dose can be changed at the next application. An implanted pellet cannot. If concentrations run high, or hematocrit climbs, the options are to wait it out or to remove the implant surgically. The polycythemia case in the pellet study is exactly the scenario where that matters — the most common side effect of testosterone therapy is one that is managed by adjusting treatment.

The mirror-image argument is just as real: a man who will not apply a spray every morning gets nothing from its adjustability. Adherence to topical therapy is measurable and imperfect,[4] and a pellet's whole advantage is that it removes daily adherence from the equation for four months.

What each is actually good for

Pellets suit a man who is stable on a known dose, wants to stop thinking about it, and accepts a minor procedure three or four times a year.

A daily spray suits a man who is still titrating, who has a reason to want the dose adjustable, who shares a household and can manage the transfer precautions, or who simply prefers no procedure.

The Endocrine Society frames formulation choice around pharmacokinetics, patient preference, formulation-specific adverse effects, treatment burden and cost.[5] Pellets and sprays sit at opposite ends of burden and opposite ends of adjustability, and neither wins on both.

Bottom line

The pellet evidence supports what pellets claim: adequate testosterone concentrations for about four months from one implantation, in a small open-label study, with fluctuation in the first fortnight and a lack of prospective controlled data behind common practice.[2]

The spray claims something different — daily, adjustable, no procedure. Choosing between them is choosing between committing to a dose and keeping the ability to change it. That is a genuine trade-off, and where a metered spray fits in the wider set of options is set out in ninety years of delivery methods.

References

5 sources

1. Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212. doi:10.1530/EJE-19-0071 · PMID 30959485
2. McMahon CG, Shusterman N, Cohen B. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency. J Sex Med. 2017;14(7):883–890. doi:10.1016/j.jsxm.2017.04.734 · PMID 28673432
3. Chik Z, Johnston A, Tucker AT, et al. Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males. Br J Clin Pharmacol. 2006;61(3):275–279. doi:10.1111/j.1365-2125.2005.02542.x · PMID 16487220
4. Grabner M, Hepp Z, Raval A, et al. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism. J Sex Med. 2018;15(2):148–158. doi:10.1016/j.jsxm.2017.11.225 · PMID 29425664
5. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364